Stockscreener 앱 받기
3.47
0.29%
-0.010
시간 외 거래:
3.42
-0.05
-1.44%
Cabaletta Bio Inc 주식(CABA)의 최신 뉴스
Will Cabaletta Bio (NASDAQ:CABA) Spend Its Cash Wisely? - Moomoo
Cabaletta Bio Takes Autoimmune Cell Therapy Pitch to Investors - MyChesCo
TD Cowen Maintains Cabaletta Bio(CABA.US) With Buy Rating - Moomoo
CABA Reiterated by HC Wainwright & Co. -- Price Target Maintained at $16 - GuruFocus
Cabaletta Bio to Participate in Upcoming Investor Conferences - Yahoo Finance
Cabaletta Bio Inc (NASDAQ: CABA) Share Price, CABA Stock News, CABA Share Price & Updates - Kalkine
Morgan Stanley Maintains Cabaletta Bio(CABA.US) With Buy Rating, Maintains Target Price $13 - Moomoo
Cabaletta Bio Inc. (CABA) Key Financial Ratios – Valuation, Profitability & More - Value Research
Cabaletta Bio Inc (CABA) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Cabaletta (CABA) Earnings Reading: EPS Lands Above Forecast in the Current Update; Post-Report: Shares Finish 0.96% Down in the Available RecordProfit Growth Outlook - vinanet.vn
Blue Owl Capital Holdings LP Acquires New Holdings in Cabaletta Bio, Inc. $CABA - MarketBeat
WuXi Bio to offload chromatography unit; Cabaletta names another CDMO partner - Endpoints News
Cabaletta Targets 2027 BLA as Cell Therapy Trials Advance - MyChesCo
Cabaletta Bio (NASDAQ:CABA) Trading 10.3% HigherShould You Buy? - MarketBeat
Norges Bank Initiates New Position in Cabaletta Bio (CABA) With 8.7 Million Share Purchase - GuruFocus
CABA Stock On Track For Best Day In 6 Months After Positive Early Results From Cell Therapy Trial - Stocktwits
Cabaletta Bio (CABA) Rallies 5% as Biotech Sentiment ImprovesForce Index - vinanet.vn
HC Wainwright Raises Earnings Estimates for Cabaletta Bio - MarketBeat
Cabaletta Bio (CABA) Reports Promising Phase 1/2 Data Amid Unpro - GuruFocus
668,563 Shares in Cabaletta Bio, Inc. $CABA Bought by GSA Capital Partners LLP - MarketBeat
Cabaletta Bio, Inc. (NASDAQ:CABA) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Wells Fargo Sticks to Their Hold Rating for Cabaletta Bio (CABA) - The Globe and Mail
Cormorant Asset Management (CABA) discloses 10M-share Cabaletta Bio stake - Stock Titan
CABA Maintained by Wells Fargo -- Price Target Lowered to $3.00 - GuruFocus
Wells Fargo & Company Lowers Cabaletta Bio (NASDAQ:CABA) Price Target to $3.00 - MarketBeat
Cabaletta Bio (CABA): T. Rowe Price reports 11.6% common stock stake - Stock Titan
Caballeta Bio (CABA) stake: Bain Capital Life Sciences reports 9.99% position - Stock Titan
Guggenheim Maintains Cabaletta Bio(CABA.US) With Buy Rating, Maintains Target Price $16 - Moomoo
Cabaletta Bio Releases Q2 2026 Financial Results - AlphaStreet
Cabaletta Bio (NASDAQ:CABA) Releases Earnings Results, Beats Estimates By $0.03 EPS - MarketBeat
Cabaletta Bio stock maintains Buy rating at TD Cowen on trial progress - Investing.com
Why is Cabaletta Bio stock sliding today? By Investing.com - Investing.com Australia
Why is Cabaletta Bio stock sliding today? - Investing.com
Cabaletta Bio Reports Q2 2026 Form 10-Q Highlighting Going Concern and Funding Challenges - Kalkine Media
Cabaletta Bio, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Cabaletta Bio (CABA) Q2 Earnings Beat Expectations; Market Focuses on Growth Potential Despite Losses - GuruFocus
Form 8K Cabaletta Bio Inc For: 13 August By Investing.com - Investing.com Nigeria
Cabaletta Bio Q2 net loss widens as R&D costs rise - TradingView
Cabaletta Bio, Inc. 2Q 2026: Net loss $(51.0)M, EPS $(0.34) — 10-Q Summary - TradingView
Cabaletta Bio (CABA) lifts cash to $225M while advancing rese-cel toward BLA - Stock Titan
Cabaletta Bio Reports Second Quarter 2026 Financial Results and Provides Business Update - The Manila Times
Cabaletta Bio (NASDAQ: CABA) lifts cash to $225M while advancing CAR-T trials - Stock Titan
Cabaletta Bio reports Q2 2026 net loss of $51.0M; cash position $225.1M supports operations into mid-2027 - TradingView
CABA Q1 2026 Earnings: Narrower-than-Expected Loss Highlights Clinical-Stage FocusShare Repurchase Impact - Vinanet
Adage Capital discloses 8.43% Cabaletta Bio (CABA) stake including warrant shares - Stock Titan
Cabaletta Bio (CABA): Norges Bank reports 5.382% ownership of 8.78M shares - Stock Titan
Cabaletta Bio, Inc. expected to post a loss of 37 cents a shareEarnings Preview - TradingView
Cabaletta Bio Inc (CABA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Cabaletta Bio, Inc. Stock 12‑Month Price Target Raised to $14.71, Implies 427% Upside - TradingView
Renaissance Technologies LLC Acquires 514,080 Shares of Cabaletta Bio, Inc. $CABA - MarketBeat
CABA Q2'26 Earnings: EPS estimate is (0.37) USD - TradingView
Vanguard Capital Management (CABA) discloses 8.30M-share passive stake in Cabaletta Bio - Stock Titan
CABA Q2'26 Earnings: revenue estimate is 0 USD - TradingView
CABA|Cabaletta Bio Inc|Price:2.720|Chg%:+0.030 - TradingKey
BlackRock (CABA) discloses 9.6M Cabaletta Bio shares under sole control - Stock Titan
Cabaletta Bio Inc (CABA) Earnings Date & Reports & Earnings News - TradingKey
0.86%
0.31%
자본화:
|
볼륨(24시간):